AMCA Data Breach Victim List Continues To Grow—What A Mess!

by Jondavid Klipp | Aug 15, 2019 | AMCA, Cybercrime

AMCA Data Breach Victim List Continues To Grow—What A Mess!

The list of laboratories affected by the data breach at American Medical Collection Agency (AMCA), which filed for bankruptcy on June 17, continues to grow. So far, at least 24 labs and more than 25 million patients are estimated to have been affected by the incident.

AMCA had been the nation’s largest debt collector for past-due lab test bills. Hackers gained access to AMCA’s online payment system between Aug. 1, 2018 and March 30, 2019. The target was patient credit card information, which is now being sold on the dark web (see LE, July 2019).

In addition to Quest Diagnostics, LabCorp and BioReference Labs, other former AMCA lab clients affected by the hack include many of Sonic Healthcare USA’s subsidiary labs including Clinical Pathology Labs, Sunrise Medical Labs, CBLPath and American Esoteric Labs. In addition, Sonic acquired Aurora Diagnostics in January and many of its subsidiary labs had been AMCA clients as well. Other labs affected by the breach include CompuNet Clinical Labs, Inform Diagnostics, Natera and Penobscot Community Health Center in Maine.

The AMCA data breach is a huge headache for both the legal and information technology departments at affected labs. For example, Quest Diagnostics says that approximately 31 class action lawsuits related to the AMCA data hack have been filed against it. In addition, Attorneys General
offices from numerous states and the District of Columbia and certain U.S. senators are investigating the situation and requesting information from affected labs.

And finally, there is also the question of what happens to the legitimate past-due balances owed by more than 25 million patients to the affected labs? Assuming an average past-due balance of $20 per patient and a collection rate of 10% suggest there might be a total of $50 million worth of
writeoffs incurred by former AMCA lab clients.

True Health Files For Chapter 11 Bankruptcy

by Jondavid Klipp | Aug 15, 2019 | True Health

True Health Files For Chapter 11 Bankruptcy

True Health Diagnostics (Frisco, TX) filed for Chapter 11 bankruptcy protection on July 30, blaming CMS’s suspension of its Medicare payments since May 2017.

In its bankruptcy filing, True Health said it had less than $50,000 of assets, and more than $100 million in liabilities. The company’s largest unsecured creditors include the investment bank Houlihan Lokey Capital (owed $2 million), Roche Diagnostics ($1.8 million) and the law firm Perkins
Coie ($1.3 million).

True Health, which markets advanced lipid test panels, was founded in 2014 by its CEO Chris Grottenthaler. The company jumped in size when it purchased Health Diagnostics Laboratory (HDL-Richmond, VA) for $37 million from a bankruptcy court auction in late 2015. HDL went bankrupt in June 2015 soon after agreeing to pay the federal government $47 million to settle claims it paid kickbacks to physicians in the form of a $20 per specimen process and handling fee.

True Health operates a small lab and administrative office in the Dallas area and a 100,000-squarefoot lab in Richmond. Prior to its Medicare suspension of payments, the company had a total of 400 employees and estimated annual revenue of approximately $80-$100 million, including more
than $25 million from Medicare.

True Health’s problems began in May 2017 when CMS suspended its Medicare payments on the basis of “credible allegations of fraud.” As part of this suspension, CMS imposed a 100% hold of all Medicare payments to True Health for services rendered to Medicare beneficiaries. At the time, this
amounted to approximately $2 million per month, or about 30% of True Health’s total revenue.

In June 2017, CMS reduced the suspension to 35% of Medicare payments, withholding roughly $800,000 per month from True Health. But this June, CMS raised the suspension back up to 100% once again based on “credible allegations of fraud.”

True Health filed a lawsuit against CMS in early July seeking an emergency motion for a temporary restraining order. The company contends that it never received an adequate opportunity to challenge the merits of the suspension. “This Kafka-esque system, under which CMS can withhold over $20 million without an explanation or an opportunity to challenge the suspension, and continually extend and complicate the suspension…has left True Health in financial ruin,” according to the lawsuit.

A federal court dismissed True Health’s lawsuit on July 22, enabling CMS to continue withholding payments. True Health laid off 80 employees on July 29, and says that unless additional funding is found or a “white knight” appears, it may need to shut down by the end of September.

Prior to its problems with CMS, True Health had quickly risen to the top of advanced lipid testing labs. True Health served 66,890 Medicare beneficiaries in 2016 and received $41.2 million in Medicare Part B payments, according to data from CMS.

Technical Rates for Many Pathology Services To Get Small Boost Under Proposed MPFS

by Jondavid Klipp | Aug 15, 2019 | Laboratory Market Research

Technical Rates for Many Pathology Services To Get Small Boost Under Proposed MPFS

The Proposed Medicare Physician Fee Schedule (MPFS) for 2020 includes a 5% hike to the technical component for CPT 88305, which, if finalized, would raise it to $32.12. Meanwhile, the rate for the professional interpretation is being lowered by a proposed 1% to $39.34. Overall, the global rate for CPT 88305 will increase by a proposed 2% to $71.46.

In general, technical component fees for many key surgical pathology
services (e.g., CPT 88305, 88307 and 88309) and special stains (e.g., CPT
88312 & 88313) are proposed to increase, while most professional interpretation rates are set for no change or small reductions.

Meanwhile, a few areas where pathologists and labs will see significant
rate reductions are cytopathology, flow cytometry and prostate biopsies.

ACLA Wins Appeals Court Decision; HHS Likely To Request Rehearing

by Jondavid Klipp | Aug 15, 2019 | ACLA, HHS

ACLA Wins Appeals Court Decision; HHS Likely To Request Rehearing

On July 30, the U.S. Court of Appeals for the District of Columbia ruled in favor of the American Clinical Laboratory Assn. (ACLA) in its suit against the U.S. Department of Health and Human Services (HHS) regarding implementation of the Protecting Access to Medicare Act (PAMA). The ruling overturned a D.C. District Court decision that dismissed ACLA’s lawsuit on the grounds that PAMA law prohibits judicial review of CMS’s “establishment of payment amounts” for clinical lab tests.

However, before the case goes back to D.C. District Court for review on its
merits, HHS is likely to request either a rehearing of the D.C. Court of Appeals’ three-judge panel decision or petition for a rehearing en banc from a broader panel of judges.

The D.C. Court of Appeals concluded that the statutory provision stripping jurisdiction to review payment amounts does not cover the statute’s data-collection provision. It ruled that the case be sent back to D.C. District Court to determine whether or not HHS/CMS violated PAMA by excluding hospital outreach labs from the first private-payer payment survey used to set Medicare CLFS rates for 2018 to 2020.

HHS has 45 days to petition for either a rehearing or rehearing en banc. The D.C. Court of Appeals has ordered that the case be held from being sent back to the D.C. District Court “until seven days after disposition of any timely request for rehearing or petition for rehearing en banc.”

It’s unlikely that any request by HHS for a rehearing will be granted, but the process will delay final resolution of the lawsuit, which is now approaching two years since initially being filed in late 2017.

More likely than not, the D.C. Court of Appeals will uphold its initial decision and send the lawsuit back to D.C. District Court. But the D.C. District Court proceedings could be lengthy, taking anywhere from six months to more than two years, before a decision is rendered.

Nonetheless, the Appeals Court decision is a victory for ACLA that will put pressure on HHS/CMS to negotiate with ACLA for a potential settlement of the lawsuit. ACLA and its biggest members, LabCorp and Quest Diagnostics, are lobbying hard to delay the next private-payer payment data reporting period (currently scheduled for January 1 to March 31, 2020) by one year. In addition, the lab industry wants CMS to use statistical sampling when it calculates new CLFS rates for 2021 to ensure that all lab segments (independents, hospital outreach labs and POLs) are properly represented.

Top 20 Medi-Cal Laboratories

by Jondavid Klipp | Jun 15, 2019 | Laboratory Market Research, Medi-Cal

Top 20 Medi-Cal Laboratories

The largest Medi-Cal lab provider is The Genetic Disease Screening Program (GDSP) of the California Department of Health, which received $29.5 million of Medi-Cal FFS payments in calendar year 2018, according to the latest available data from DHCS. The Genetic Disease Screening Program provides prenatal and newborn testing services to Medi-Cal recipients.

Quest Diagnostics is second largest, with $29.4 million of Medi-Cal FFS payments. Planned Parenthood, which tests for sexually transmitted diseases, received $24.7 million, followed by LabCorp at $8.8 million.

The largest academic medical centers and hospital outreach labs on the list are Dignity Health, with $3.3 million of payments, followed by Children’s Hospital of Los Angeles, $2.5 million, and Loma Linda University, $2.2 million.
In total, the top 20 lab organizations collected $127.9 million of Medi-Cal lab test payments for FFS patients in 2018.